Market Overview

Tesaro Shares Tumble After Disappointing Data Results

Related TSRO
Mid-Afternoon Market Update: Gas Natural Jumps After Merger News; Twilio Shares Drop
The ESMO Conference Proves Its Ability To Move Stocks

Shares of Tesaro (NASDAQ: TSRO) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints.

BMO Capital Markets analyst Jim Birchenough reported that investors had expected Tesaro's rolapitant to differentiate itself from other treatments for CINV based on nausea benefit which didn't reach statistical significance. Birchenough added that a better dosing schedule and the absence of reactions may not be enough to differentiate from Merck's Emend.

Tesaro closed at $37.70 on Friday.

Latest Ratings for TSRO

Oct 2016Bank of AmericaUpgradesNeutralBuy
Oct 2016Leerink SwannMaintainsOutperform
Oct 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Jim BirchenoughAnalyst Color Analyst Ratings


Related Articles (TSRO)

View Comments and Join the Discussion!